GlassScriptPhysician profile
Stephanie J Herrera
NPI 1821562356
$3,593.68
in general payments reported to CMS, 2019-2025
17 companies · $186 in 2025
The $186 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $468 · 2022: $274 · 2023: $832 · 2024: $1,834 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,851.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,347.67 | 2023-2024 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $581.36 | 2021-2024 | |
| Glaxosmithkline, LLC. | $233.53 | 2021-2025 | Nucala |
| Janssen Scientific Affairs, LLC | $210.11 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $183.48 | 2021-2025 | Lupkynis |
| Janssen Biotech, INC. | $181.58 | 2021-2024 | Tremfya, Simponi Aria |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $175.79 | 2023-2024 | Caplyta |
| Novartis Pharmaceuticals Corporation | $166.85 | 2024 | |
| Gilead Sciences, INC. | $121.81 | 2024 | Vemlidy |
| Aspira Women'S Health INC | $97.63 | 2024 | Ova1 |
| Astrazeneca Pharmaceuticals LP | $96.51 | 2025 | |
| Lilly USA, LLC | $84.68 | 2024 | Taltz, Zepbound |
| Fresenius Kabi USA, LLC | $34.09 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.98 | 2024 | Cyltezo |
| Pfizer INC. | $23.72 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $15.51 | 2023 | Strensiq |
| Mallinckrodt Hospital Products INC. | $14.38 | 2023 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Herrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.